KMD Bioscience Co., Ltd.
400-621-6806
Service Line：+86-022-82164980
Address：FL-4, Building A5, International Enterprise Community, Tianjin, China
Email：[email protected]
| Catalog Number | YR1301 |
|---|---|
| Product Name | Anti-Human ACVR2A & ACVR2B Recombinant Antibody |
| Molecular Name | Bimagrumab |
| Alias | Anti-ACVR2A & ACVR2B Recombinant Antibody, Research Grade Bimagrumab |
| CAS Number | 1356922-05-8 |
| Target | ACVR2A & ACVR2B[Homo sapiens] |
| Isotype | IgG1 Lambda |
| Clonity | Monoclonal |
| Source | CHO Cells |
| Size | 1mg, 5mg |
| Concentration | 1mg/ml |
| Purity | >95% as determined by SDS-PAGE |
| Applications | FCM, IP, ELISA, Neut, FuncS, IF, ICC, MRI |
| Buffer | PBS, pH7.5 |
| Background | Bimagrumab (BYM338) is a human monoclonal antibody developed by Novartis to treat pathological muscle loss and weakness. On August 20, 2013, it was announced that bimagrumab had received a breakthrough therapy designation for sporadic inclusion body myositis (sIBM) by the US Food and Drug Administration. |
| Storage | It is recommended to aliquote and store at -20°C for long term storage. Avoid repeated freezing and thawing cycles. |
| Note | This product is for research use only. |
FL-4, Building A5, International Enterprise Community, Tianjin, China
Email：[email protected]
Hot Line： +86-022-82164980
Technical Support：[email protected]
